Recent Advances in CAR T-cell Therapy for Lymphoma in China

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2023 Apr 16

PMID 37062016

Authors

Yuxuan Che

Xiuhua Sun

Affiliations

Soon will be listed here.

Abstract

Lymphoma is a hematologic malignancy which mainly consists of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Although systemic chemotherapy, radiotherapy, and other advanced therapeutics, including rituximab or immune checkpoint inhibitors, have improved the prognosis in recent decades, there are still a number of patients with relapsed or refractory (R/R) lymphoma with a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy has provided a curative option for patients with relapsed or refractory lymphoma. Numerous clinical trials have been conducted worldwide and presented inspiring results that give insight into this breakthrough therapy. The development of cancer cell therapy in China has been rapid in the past years and dominates the field with the USA. This review aims to summarize the published results of CAR T-cell therapy alone or in combination with other therapies in mainland China, both in R/R NHL and R/R HL.

Citing Articles

Broadening the horizon: potential applications of CAR-T cells beyond current indications.

Karsten H, Matrisch L, Cichutek S, Fiedler W, Alsdorf W, Block A Front Immunol. 2023; 14:1285406.

PMID: 38090582 PMC: 10711079. DOI: 10.3389/fimmu.2023.1285406.

References

Grignano E, Laurent J, Deau B, Burroni B, Bouscary D, Kirova Y . The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high-risk diffuse large B-cell lymphoma. Eur J Haematol. 2018; . DOI: 10.1111/ejh.13080. View

Zeng C, Cheng J, Li T, Huang J, Li C, Jiang L . Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Cytotherapy. 2020; 22(3):166-171. DOI: 10.1016/j.jcyt.2020.01.008. View

Wang C, Wu Z, Wang Y, Guo Y, Dai H, Wang X . Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. Clin Cancer Res. 2016; 23(5):1156-1166. DOI: 10.1158/1078-0432.CCR-16-1365. View

Chiarle R, Podda A, Prolla G, Gong J, Thorbecke G, Inghirami G . CD30 in normal and neoplastic cells. Clin Immunol. 1999; 90(2):157-64. DOI: 10.1006/clim.1998.4636. View

Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M . Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2016; 52(2):216-221. DOI: 10.1038/bmt.2016.213. View

Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y . Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood. 2020; 136(14):1632-1644. PMC: 7596761. DOI: 10.1182/blood.2020005278. View

Schwab U, STEIN H, Gerdes J, Lemke H, Kirchner H, Schaadt M . Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982; 299(5878):65-7. DOI: 10.1038/299065a0. View

Chen W, Zheng R, Zhang S, Zeng H, Xia C, Zuo T . Cancer incidence and mortality in China, 2013. Cancer Lett. 2017; 401:63-71. DOI: 10.1016/j.canlet.2017.04.024. View

Kochenderfer J, Rosenberg S . Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013; 10(5):267-76. PMC: 6322669. DOI: 10.1038/nrclinonc.2013.46. View

10.

Sadelain M, Riviere I, Brentjens R . Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003; 3(1):35-45. DOI: 10.1038/nrc971. View

11.

Kochenderfer J, Somerville R, Lu T, Yang J, Sherry R, Feldman S . Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther. 2017; 25(10):2245-2253. PMC: 5628864. DOI: 10.1016/j.ymthe.2017.07.004. View

12.

Wei G, Zhang Y, Zhao H, Wang Y, Liu Y, Liang B . CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. Cancer Immunol Res. 2021; 9(9):1061-1070. DOI: 10.1158/2326-6066.CIR-20-0675. View

13.

Elstrom R, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R . Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk. 2010; 10(3):192-6. DOI: 10.3816/CLML.2010.n.030. View

14.

Lohri A, Barnett M, Fairey R, OReilly S, Phillips G, Reece D . Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood. 1991; 77(10):2292-8. View

15.

Majzner R, Mackall C . Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov. 2018; 8(10):1219-1226. DOI: 10.1158/2159-8290.CD-18-0442. View

16.

Xiao X, Jiang Y, Cao Y, Li Q, Jin X, Meng J . [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2019; 40(4):276-280. PMC: 7343005. DOI: 10.3760/cma.j.issn.0253-2727.2019.04.003. View

17.

Wang Y, Zhang W, Han Q, Liu Y, Dai H, Guo Y . Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol. 2014; 155(2):160-75. DOI: 10.1016/j.clim.2014.10.002. View

18.

Wang D, Zeng C, Xu B, Xu J, Wang J, Jiang L . Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30 lymphoma patients. Blood Cancer J. 2020; 10(1):8. PMC: 6978321. DOI: 10.1038/s41408-020-0274-9. View

19.

Qu C, Ping N, Kang L, Liu H, Qin S, Wu Q . Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden. J Immunother. 2019; 43(1):32-37. DOI: 10.1097/CJI.0000000000000284. View

20.

Viviani S, Zinzani P, Rambaldi A, Brusamolino E, Levis A, Bonfante V . ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011; 365(3):203-12. DOI: 10.1056/NEJMoa1100340. View